Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Crude Oil Rises on Virus Drug Trial, Lower Rise in Inventories

Published 04/29/2020, 10:05 AM
Updated 04/29/2020, 10:52 AM
© Reuters.
GILD
-
MS
-
LCO
-
CL
-

By Peter Nurse and Kim Khan

Investing.com - Oil markets headed higher Wednesday, rebounding as positive news from trials of a potential treatment for the Covid-19 virus fostered hopes of a quick rebound in fuel demand from the travel and leisure sector. 

Gilead Sciences (NASDAQ:GILD) said it was "aware of positive data"  emerging from the National Institute of Allergy and Infectious Diseases’ study of its antiviral drug remdesivir for the treatment of Covid-19. The company said results showed it benefited patients who took the drug at an early stage of the illness, although later-stage patients responded less.

In addition, a smaller than expected rise in U.S. oil inventories of 9 million barrels took some pressure off the front-month contracts, which has seen selling from dwindling storage space for crude.

“It appears like curves are being flattened everywhere and the curve on crude stocks’ build is the latest to experience this phenomenon, declining from the previous week’s 15-million-barrel jump,” Investing.com analyst Barani Krishnan said.

At 10:45 AM ET (1405 GMT), U.S. crude futures traded 34% higher at $16.59 a barrel, while the international benchmark Brent contract rose 8.6% to $24.70.

In the U.S., the world’s largest consumer of crude, an increasing number of U.S. states start reopening their economies as the administration ramps up the number of virus tests available, and this is being matched in Europe.

This is helping the market rebound, to a degree, after losing more than a quarter of its value over the past two days amid concerns prices may again drop below zero and as investors and a major fund exited the June contract - there were 318,000 open positions as of Tuesday, with 15 sessions left before expiration. May WTI had 610,000 at the same point before expiry.

But oil inventories rose by a beleow-trend 9 million barrels for the week ended April 24, the EIA said. That compared with expectations for a build of about 10.6 million barrels, according to forecasts compiled by Investing.com and down from an average of about 16 million barrels in the past few weeks.

Gasoline inventories unexpectedly sank by 3.7 million barrels, versus forecasts for a rise of about 2.5 million barrels. Distillate stockpiles rose by 5.1 million barrels, compared with expectations for a build of about 3.6 million barrels.

Stockpiles at the Cushing, Okla. hub rose by 3.7 million barrels versus 5 million the week before.

“That’s a relief of sorts for anyone watching the Cushing numbers to guess on how long it takes before the hub runs out of space altogether for physical WTI deliveries,” Krishan said.

“On production, the other big number everyone’s been looking out for, we have a 100,000-barrel-per-day decline, putting us finally at 1 million barrels from the record high 13.1 bpd in mid-March,” he added. “It’s still a pretty slow retreat but it’s the best we have for now, given how the EIA estimates these things.”

The headwinds to physical demand were visible in the latest U.S. economic data. Gross domestic product data showed the U.S. economy contracted by 4.8% in the first quarter. Shorter-cycle data strongly suggest that the second quarter is going to be even worse. 

But market forces are exerting ever-greater pressure on producers. China’s three biggest state producers have announced they will slash their spending plans this year by a combined $19 billion, in the latest sign companies are having to take drastic measures to weather the crash in demand and prices.

Production cuts both inside and outside of the OPEC+ bloc are widely expected to help restore some kind of balance to the market in due course. Analysts at Morgan Stanley (NYSE:MS) said Wednesday they see WTI stabilizing at around $40 a barrel in 2021, with Brent around $5/bbl higher.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.